SPB3_HUMAN SERPINB3 ELISA tesk kit
- Known as:
- SPB3_HUMAN SERPINB3 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen17319
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- SPB3_HUMAN SERPINB3 ELISA tesk kit
Related genes to: SPB3_HUMAN SERPINB3 ELISA tesk kit
- Gene:
- SERPINB3 NIH gene
- Name:
- serpin family B member 3
- Previous symbol:
- SCC, SCCA1
- Synonyms:
- T4-A, HsT1196
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-15
- Date modifiied:
- 2016-10-05
Related products to: SPB3_HUMAN SERPINB3 ELISA tesk kit
Related articles to: SPB3_HUMAN SERPINB3 ELISA tesk kit
- To evaluate the serum expression of SerpinB3/B4/B10 and serum level of interleukin-17 as biomarkers for chronic rhinosinusitis with nasal polyps. - Source: PubMed
Publication date: 2026/05/26
Hussein Hossam AdelHabieb Mona SHamdan Ahmad M - Penile cancer is a rare malignancy, and multicenter data evaluating prognostic biomarkers in the Japanese population are limited. This study aimed to assess the prognostic significance of pretreatment blood-based biomarkers in patients with penile cancer. - Source: PubMed
Tatarano ShuichiMiyake MakitoOsaki YuDaizumoto KeiWada KoichiroKobayashi KeitaKato MinoruFukuhara HideoTsujino TakuyaKobatake KoheiTaoka RikiyaFurukawa JunyaOgawa KoheiShiraishi KojiMatsue TaisukeInoue KeijiMaenosono RyoichiSekino YoheiFujimoto KiyohideEnokida Hideki - Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC). - Source: PubMed
Publication date: 2026/05/01
Lyu NanWang QianqianJiang KuirongXu DongWu YangZhang KaiWei JishuChen JianminGuo FengLu ZipengXiao BinChen GuoshengWu JunliGao WentaoWang YuqiWang FufengTu Min - MASLD and HCC are increasing challenges in hepatology. 1-Piperidinepropionic acid (1-PPA), a protease-activated receptor 2 (PAR2) inhibitor, downregulates SerpinB3, a molecule involved in fibrosis and HCC. This study investigates the effects of 1-PPA on lipid accumulation and HCC development. - Source: PubMed
Publication date: 2026/04/22
Guerra PietroVillano GianmarcoRejano-Gordillo Claudia MGil-Pitarch ClàudiaRuvoletto MariagraziaBiasiolo AlessandraQuarta SantinaZapata-Pavas L EstefaníaPeña-SanFelix PatriciaGonzález-Recio IreneGoikoetxea-Usandizaga NaroaBarrenechea-Barrenechea Jon AnderSanz-Parra ArantzaGambella AlessandroDe Siervi SilviaOliviero BarbaraMantovani StefaniaNurcis JessicaCagnin SilviaMartini AndreaTurato CristianCannito StefaniaGuido MariaParola MaurizioMartínez-Chantar María LuzPontisso Patrizia - The pharmacological mechanism of leonurine (LEO) in treating hypoxic pulmonary hypertension (HPH) remained unclear. We established a rat model of HPH to assess the preliminary therapeutic effects of LEO. We examined how LEO alters cell populations and affects S100A9 expression in lung tissue using single cell RNA sequencing. We developed an in vitro model of neutrophil activation and migration and a co-culture system of neutrophils and pulmonary artery endothelial cells (PAECs) to investigate the mechanistic basis of this process. We also employed molecular docking, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTS) to identify the molecular target and used gene silencing approach to validate the mechanism. LEO treatment significantly alleviated associated pathological changes in lung tissue. LEO suppressed hypoxia-induced S100A9 production in neutrophils. Interestingly, LEO did not directly mitigate PAEC dysfunction. However, supernatants from LEO-treated neutrophils significantly reduced the expression of inflammatory cytokines, as well as the mesenchymal marker VIM, in PAECs. Subsequent molecular docking, CETSA, and DARTS experiments demonstrated that LEO directly binds to SERPINB3 in vitro and inhibits downstream STAT1/3 phosphorylation. Silencing Serpinb3 attenuated the ability of LEO on neutrophil migration and S100A9 production and on PAEC dysfunction. LEO targeted SERPINB3 to inhibit S100A9 production in neutrophils, thereby attenuating endothelial dysfunction and vascular remodeling in HPH. - Source: PubMed
Publication date: 2026/03/06
Cui HuantianMin FeitianDeng HongyuWang YumingLi HanzhouPei HuanZhang CongmeiLong YuanFang XixingLiang RuiminWan QianqianCui ZhifangYang BaoWang Ning